CNR2 and lung disorder: Even though this is not related to the inflammatory process of lung disease, the study will provide more information on this potential drug class as a whole and give insight on pharmacokinetic and pharmacodynamic effects of a CB2 agonist in humans (RaQualia Pharma Inc, 2023).